Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
{{TOCright}}
{{TOCright}}
=Celera=
=Celera=
=Amgen=
=Amgen=
* Headquarters: Thousand Oaks, CA
* Headquarters: Thousand Oaks, CA
Line 49: Line 51:
* Owned by Swiss pharma company Hoffman - La Roche ([http://en.wikipedia.org/wiki/Hoffmann-La_Roche Hoffman-La Rouche])
* Owned by Swiss pharma company Hoffman - La Roche ([http://en.wikipedia.org/wiki/Hoffmann-La_Roche Hoffman-La Rouche])
* synthetic human insulin was their first famous product, many others produced using the Boyer-Cohen rDNA process  
* synthetic human insulin was their first famous product, many others produced using the Boyer-Cohen rDNA process  
* Papers by company employees: http://en.scientificcommons.org/genentech_inc
* [http://en.scientificcommons.org/genentech_inc Papers by] company employees
*Others/Notes:
*Others/Notes:
** Collaborated with Apple to create Open Source search engine for protein and DNA sequences (http://www.apple.com/ca/press/2002/02/genentech.html) called [http://www.apple.com/downloads/macosx/math_science/agblast.html Apple/Genentech BLAST]
** [http://www.apple.com/ca/press/2002/02/genentech.html Collaborated with Apple] to create Open Source search engine for protein and DNA sequences  called [http://www.apple.com/downloads/macosx/math_science/agblast.html Apple/Genentech BLAST]
** Hoffman-La Rouche is engaging in academic collaboration to study the safety of InnoMed PredTox ("Hoffman-La Rouche," Wikipedia)
** Hoffman-La Rouche is engaging in academic collaboration to study the safety of InnoMed PredTox ("Hoffman-La Rouche," Wikipedia)
* In general, this seems to be a company that [http://www.gene.com/gene/research/researchvision.html encourages its scientists to publish]  
* In general, this seems to be a company that [http://www.gene.com/gene/research/researchvision.html encourages its scientists to publish]  
** [http://en.scientificcommons.org/genentech_inc examples of papers]  
** [http://en.scientificcommons.org/genentech_inc examples of papers]  
** [http://ecorner.stanford.edu/authorMaterialInfo.html?mid=1614 Video of Genentech's Joe McCracken explaining incentives to publish]
** [http://ecorner.stanford.edu/authorMaterialInfo.html?mid=1614 Video of Genentech's Joe McCracken explaining incentives to publish]
* [http://www.gene.com/gene/research/researchvision.html It has four-year post-doctoral program] and also offers [http://www.gene.com/gene/pipeline/fellowship/ Clinical Research Fellowships]  
** [http://www.gene.com/gene/research/researchvision.html It has four-year post-doctoral program] and also offers [http://www.gene.com/gene/pipeline/fellowship/ Clinical Research Fellowships]  
* supplies reagents for other research organizations' work: http://www.gene.com/gene/reagents-program/reagents-program.jsp
** [http://www.gene.com/gene/reagents-program/reagents-program.jsp Supplies reagents] for other research organizations' work
* Seems committed to engaging relevant stake-holders in public policy issues. Worked with the American Academy of Opthamology and the American Society of Retina Specialists to develop guidelines and answer questions about Avastin (http://www.gene.com/gene/news/press-releases/press_statements/ps_122007.html)
** [http://www.gene.com/gene/news/press-releases/press_statements/ps_122007.html Worked with] the American Academy of Ophthalmology and the American Society of Retina Specialists to develop guidelines and answer questions about Avastin  
* Has a separate board to advise the company on issues of scientific research (http://www.gene.com/gene/research/resourceboard/)
** Has a [http://www.gene.com/gene/research/resourceboard/ separate board] to advise the company on issues of scientific research  
* company gives researchers 20% free time to work on projects of their own
** Company gives researchers 20% free time to work on projects of their own
* VP for business development says the organization survives through science, not marketing.
** VP for business development [http://ecorner.stanford.edu/authorMaterialInfo.html?mid=1613 says] the organization survives through science, not marketing.
** http://ecorner.stanford.edu/authorMaterialInfo.html?mid=1613
** [http://www.universityofcalifornia.edu/news/article/19205 Collaboration] with UC San Diego Scientists
* Collaboration with UC San Diego Scientists (http://www.universityofcalifornia.edu/news/article/19205)
** Funds undergraduate research programs through the [http://www.genentechfoundation.com/about_focus.html Genentech Foundation]
* Funding for undergraduate research programs (http://www.genentechfoundation.com/about_focus.html)
** Provids [http://news.ucsf.edu/releases/new-ucsf-mission-bay-campus-countrys-largest-biomedical-university-expansio/ infrastructure support] for UCSF
* Providing infrastructure support for UCSF (http://news.ucsf.edu/releases/new-ucsf-mission-bay-campus-countrys-largest-biomedical-university-expansio/)
** [http://www.scienceblog.com/community/older/2000/D/200003674.html Collaboration with Rockefeller University] to look at therapeutic antibody potency
* Collaboration with Rockefeller University to look at therapeutic antibody potency (http://www.scienceblog.com/community/older/2000/D/200003674.html)


==Genzyme==
=Genzyme=
===Who===
* Headquarter Cambridge
* 2007, US$2.89B operating income, $3.81B revenue ("Genzyme," Wikipedia)
* 2007, US$2.89B operating income, $3.81B revenue ("Genzyme," Wikipedia)
===What===
* Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue  
* Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue  
* Renagel, for dialysis patients
* Renagel, for dialysis patients
*Fabrazyme, for Fabry's disease
* Fabrazyme, for Fabry's disease
 
* Other/Notes:
===Where===
** Develops community support groups for victims of the diseases it treats, such as [http://www.fabrycommunity.com/en/ Fabry Community] and other at [http://www.genzyme.com/home/global_sites.asp Genzyme Disease Education/Research/Support Sites]
*Cambridge
** Has established [https://www.lsdregistry.net/gaucherregistry/ for victims of Gaucher's disease]
===News===
** All company-sponsored clinical trials registered [www.clinicaltrials.gov Clinical Trials] and at [http://www.genzymeclinicalresearch.com/ Genzyme Clinical Research]
===Commons-Based, Peer-Production, and Open Access News===
** [http://www.genzyme.com/research/patents/pat_home.asp Partial catalog of researchers' publications]
* Developing community support groups for victims of the diseases it treats (e.g. http://www.fabrycommunity.com/global/fc_p_hp_homepage.asp)
** Give [http://www.genzyme.com/commitment/community/grant_application.asp grants] for science education and health-services in local communities
**Complete list of communities at: http://www.genzyme.com/home/global_sites.asp
** [http://www.genzyme.com/corp/media/GENZ%20PR-042208.asp#TopOfPage Building outreach into China]. Will establish research center there by 2010.
* Has established registry for victims of Gaucher's disease (https://www.lsdregistry.net/gaucherregistry/)
* All company-sponsored clinical trials registered at www.clinicaltrials.gov (http://www.genzymeclinicalresearch.com/)
* Partial catalog of researchers' publications (http://www.genzyme.com/research/patents/pat_home.asp)
* Grants for science education and health-services in local communities (http://www.genzyme.com/commitment/community/grant_application.asp)
* Building outreach into China. Will establish research center there by 2010. Will it support universities there? (http://www.genzyme.com/corp/media/GENZ%20PR-042208.asp#TopOfPage)
 
==Gilead Sciences==


===Who===
=Gilead Sciences=
* Headquarters: Foster City, California
* 3,400 hundred employees (http://www.gilead.com/corporate_fact_sheet)
* 3,400 hundred employees (http://www.gilead.com/corporate_fact_sheet)
* Growth based in large part on acquisition of other companies
* Growth based in large part on acquisition of other companies
===What===
* Products for HIV/AIDS, respiratory and heart conditions, and liver disease
* Products for HIV/AIDS, respiratory and heart conditions, and liver disease
* Over a dozen drugs in the development pipeline, Phase I or later
* Over a dozen drugs in the development pipeline, Phase I or later
*  
* Acquisition history:
===Where===
** 1990 reaches agreement with Glaxo to research and develop "antisense" -- genetic code blockers
* Foster City, California
** Goes public in 1992
** 1996 - first commercial product, Vistide, treats cytomegalovirus
** 1999 - acquires NeXstar Pharmaceuticals
** 2003 acquires Triangle Pharmaceuticals
** 2006, FDA approves Atripla for HIV-victims
** 2006 acquires Corus Pharma, Inc.
** 2006 acquires Myogen, Inc.
** 2006 acquires Raylo Chemicals, a pharma producer - is Gilead Sciences trying to become a pharma company?
*Other/Notes:
** Gilead seems to have created an HIV/AIDS Clinical Cooperation Grant (http://www.gilead-grant.de/disclaimer.html)
** publishes the results of clinical trials
** Collaboration with [http://today.ucsf.edu/stories/gilead-sciences-and-gladstone-to-collaborate-on-hiv-targets/ UCSF on HIV targets]
** [http://www.gilead.com/access_developing_world Project to bring HIV/AIDS drugs to third-world]
* Foundation for bringing [http://www.gilead.com/Gilead_Foundation health care to under-served communities]


===News===
=Biogen Idec=
* 1990 reaches agreement with Glaxo to research and develop "antisense" -- genetic code blockers
* Headquarters: Kendall Scquare, Cambridge
* Goes public in 1992
* from Wikipedia: commercial affiliates in "Germany, France, Spain/Portugal, UK/Ireland, the Benelux, Sweden, Denmark, Norway, Finland, and Austria"
* 1996 - first commercial product, Vistide, treats cytomegalovirus
* Research centers in San Diego and Research Triangle Park, N.C.
* 1999 - acquires NeXstar Pharmaceuticals
* 2003 acquires Triangle Pharmaceuticals
* 2006, FDA approves Atripla for HIV-victims
* 2006 acquires Corus Pharma, Inc.
* 2006 acquires Myogen, Inc.
* 2006 acquires Raylo Chemicals, a pharma producer - is Gilead Sciences trying to become a pharma company?
 
===Commons-Based, Peer-Production, and Open Access News===
* Gilead seems to have created an HIV/AIDS Clinical Cooperation Grant (http://www.gilead-grant.de/disclaimer.html)
* publishes the results of clinical trials
* Collaboration with UCSF on HIV targets (http://today.ucsf.edu/stories/gilead-sciences-and-gladstone-to-collaborate-on-hiv-targets/)
* Project to bring HIV/AIDS drugs to third-world (http://www.gilead.com/access_developing_world)
* Foundation for bringing healthcare to under-served communities (http://www.gilead.com/Gilead_Foundation)
 
==Biogen Idec==
===Who===
 
===What===
* Treatments for Multiple Sclerosis, Crohn's disease, and a treatment for non-Hodgkin's lymphoma which is co-marketed with Genentech
* Treatments for Multiple Sclerosis, Crohn's disease, and a treatment for non-Hodgkin's lymphoma which is co-marketed with Genentech
* Most revenue derived from Avonex, it's MS treatment
* Most revenue derived from Avonex, it's MS treatment
===Where===
* Kendall Scquare, Cambridge
* from Wikipedia: commercial affiliates in "Germany, France, Spain/Portugal, UK/Ireland, the Benelux, Sweden, Denmark, Norway, Finland, and Austria"
* Research centers in San Diego and Research Triangle Park, N.C.
===News===
* 2003, Biogen and IDEC merge
* 2003, Biogen and IDEC merge
 
* Others/Notes:
===Commons-Based, Peer-Production, and Open Access News===
** Gives educational grants to med schools (http://www.biogenidec.com/site/community-relations.html)
* Gives educational grants to med schools (http://www.biogenidec.com/site/community-relations.html)
** Sponsors "Citi Biotech Day" (http://www.foxbusiness.com/story/markets/industries/health-care/biogen-idec-present-th-annual-citi-biotech-day/)
* Sponsors "Citi Biotech Day" (http://www.foxbusiness.com/story/markets/industries/health-care/biogen-idec-present-th-annual-citi-biotech-day/)
** Has US$100million venture capital fund to encourage Biotech research
* Has US$100million venture capital fund to encourage Biotech research
** Cooperated with Genentech to research and produce lymphoma treatment
* Cooperated with Genentech to research and produce lymphoma treatment
** Biogen Idec Innovation Incubator (bi3) seems to be a way for Biogen to buy start-up ventures (http://www.biogenidec.com/site/biogen-idec-innovation-incubator.html)  
* Biogen Idec Innovation Incubator (bi3) seems to be a way for Biogen to buy start-up ventures (http://www.biogenidec.com/site/biogen-idec-innovation-incubator.html)  
** Student labs for high school students in Cambridge and San Diego (http://www.biogenidec.com/site/community-relations.html)
* Student labs for high school students in Cambridge and San Diego (http://www.biogenidec.com/site/community-relations.html)


==Cephalon==
==Cephalon==
===Who===
===What===
===Where===
===News===
===Commons-Based, Peer-Production, and Open Access News===


==MedImmune==
==MedImmune==
===Who===
===What===
===Where===
===News===
===Commons-Based, Peer-Production, and Open Access News===


==Celgene==
==Celgene==
===Who===
===What===
===Where===
===News===
===Commons-Based, Peer-Production, and Open Access News===


==Abraxis BioScience==
==Abraxis BioScience==
===Who===
===What===
===Where===
===News===
===Commons-Based, Peer-Production, and Open Access News===


==ImClone Systems==
==ImClone Systems==
===Who===
===What===
===Where===
===News===
===Commons-Based, Peer-Production, and Open Access News===


==Navigation==
==Navigation==
[[IP Profile of Biggest for-profit companies in BGP]]
[[IP Profile of Biggest for-profit companies in BGP]]<br>
 
[[Biotechnology - Genomic and Proteomics]]<br>
[[Biotechnology - Genomic and Proteomics]]
 
[[Main Page]]
[[Main Page]]

Revision as of 18:16, 22 April 2010

Celera

Amgen

  • Headquarters: Thousand Oaks, CA
  • 16,900 employees (2008 Corporate report)
  • History of acquisition:
    • 1994 - Synergen, Inc.
    • 2000 - Kinetix Pharmaceuticals, Inc.
    • 2002 - Immunex Corporation
    • 2004 - Tularik, Inc.
    • 2006 - Abgenix, Inc.
    • 2006 - Avidia, Inc.
    • 2007 - Ilypsa, Inc.
    • 2007 - Alantos Pharmaceuticals Holdings, Inc.
  • Subsidiaries:
    • Amgen Australia Pty Ltd.;
    • Amgen N.V.; Amgen Canada Inc.;
    • Amgen Greater China Ltd.;
    • Amgen GmbH (Germany);
    • Amgen S.A. (France);
    • Amgen S.p.A. (Italy);
    • Amgen K.K. (Japan);
    • Amgen B.V. (Netherlands);
    • Amgen-Biofarmaceutica (Portugal);
    • Amgen S.A. (Spain);
    • Amgen (Europe) AG (Switzerland);
    • Kirin-Amgen, Inc. (Switzerland);
    • Amgen Limited (U.K.);
    • Amgen Sales Corporation (West Indies).
  • Unlike many biotech companies, has been consistently profitable. Net profit in 2006 was US$2.9 Billion
  • History: **Managed to turn itself from a drug research company into a pharmaceutical company while maintaining steady sales - extremely rare in the industry.
    • Founded in 1980. By 1986 was starting to turn a profit, but did so not through drug development but through research partnerships with established pharma firms
    • 1987, develop erythropoietin (EPO), which stimulates red blood cell creation. Sold the marketing rights to Johnson&Johnson
    • Epogen proves to hugely popular - over $250m in sales in 1991 alone
    • Between 1992 and 1996, Amgen's R&D budget goes from $182 million to $663 million
  • It has ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline as of 2009
    • drugs include: Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate
  • As a side-result of this research, also publishes in academic journals
  • Others/Notes:
    • Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed
    • Seems to be engaging in some instances of open-ended research with universities. e.g., collaboration with MIT's Whitehead institute
    • Further instances of academic collaboration here
    • The results of some scientific collaborations are being released into the commons
  • It says its committed to sharing clinical testing results as soon as possible

Genentech

Genzyme

Gilead Sciences

  • Headquarters: Foster City, California
  • 3,400 hundred employees (http://www.gilead.com/corporate_fact_sheet)
  • Growth based in large part on acquisition of other companies
  • Products for HIV/AIDS, respiratory and heart conditions, and liver disease
  • Over a dozen drugs in the development pipeline, Phase I or later
  • Acquisition history:
    • 1990 reaches agreement with Glaxo to research and develop "antisense" -- genetic code blockers
    • Goes public in 1992
    • 1996 - first commercial product, Vistide, treats cytomegalovirus
    • 1999 - acquires NeXstar Pharmaceuticals
    • 2003 acquires Triangle Pharmaceuticals
    • 2006, FDA approves Atripla for HIV-victims
    • 2006 acquires Corus Pharma, Inc.
    • 2006 acquires Myogen, Inc.
    • 2006 acquires Raylo Chemicals, a pharma producer - is Gilead Sciences trying to become a pharma company?
  • Other/Notes:
  • Foundation for bringing health care to under-served communities

Biogen Idec

Cephalon

MedImmune

Celgene

Abraxis BioScience

ImClone Systems

Navigation

IP Profile of Biggest for-profit companies in BGP
Biotechnology - Genomic and Proteomics
Main Page

Retrieved from "http://cyber.harvard.edu/commonsbasedresearch/?title=Biotechnology_-_Genomic_and_Proteomics/IP_Profile_of_Biggest_for-profit_companies_in_BGP/BGP_Company_Profiles_-_Data&oldid=6831"